GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Achieve Life Sciences
Achieve Life Sciences is a biotech company developing a smoking cessation drug. Its stock price is a bet on the success of its clinical trials. The stock price reflects high volatility and dependence on FDA decisions, which could radically alter its fate.
Share prices of companies in the market segment - Narco farm
Achieve Life Sciences is developing cytisiniclin as a treatment for smoking cessation and nicotine addiction. We classify it as a "Pharmaceuticals (Narcology)" company because it targets the vast addiction treatment market. The chart below shows how investors view the prospects of this socially significant field.
Broad Market Index - GURU.Markets
Achieve Life Sciences is a biopharmaceutical company developing a treatment for smoking cessation and nicotine addiction. As a component of the GURU.Markets index, it addresses an important public health issue. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ACHV - Daily change in the company's share price Achieve Life Sciences
Change_co for Achieve, a biopharmaceutical company, measures its volatility. It reflects sensitivity to the results of clinical trials of its smoking cessation drug. This metric is a key component in the formulas on System.GURU.Markets for analyzing the biotech sector.
Daily change in the price of a set of shares in a market segment - Narco farm
Achieve Life Sciences, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with ACHV, which focuses on nicotine addiction treatment, helps to assess it as a high-risk, clinically data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Achieve Life Sciences is developing a smoking cessation drug. Given the company's vast market and the social significance of the issue, its shares can experience high volatility on news of clinical trials. These movements are part of the market dynamics driven by hopes for new drugs.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Achieve Life Sciences
For Achieve Life Sciences, the year-to-date trend is a story about developing a new smoking cessation drug. Its market capitalization over the next 12 months depends entirely on the results of the Phase III clinical trials of its drug, cytisinicline. Success in these trials could make it a leading drug in a huge market and lead to explosive growth.
Annual dynamics of market capitalization of the market segment - Narco farm
Achieve Life Sciences, Inc. is a biopharmaceutical company developing a smoking cessation drug. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs in this vast but complex field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Achieve Life Sciences is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its smoking cessation drug. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Achieve Life Sciences
Achieve Life Sciences is focused on a single product—a smoking cessation drug. Therefore, its monthly market capitalization is entirely dependent on news related to its development. Clinical trial results and interactions with the FDA are the only significant events driving the sharp ups and downs visible on this chart.
Monthly dynamics of market capitalization of the market segment - Narco farm
This chart reflects the dynamics of the volatile biotech sector. For Achieve, a single-product company, it's the backdrop. Its movements illustrate how investor expectations surrounding the results of its drug trials can drive extreme swings.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Achieve Life Sciences is developing a smoking cessation drug. Its future depends entirely on the success of clinical trials and regulatory approval. The overall market price has little impact on Achieve; its shares are driven by scientific news, which can cause explosive growth or decline, ignoring any macroeconomic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Achieve Life Sciences
Achieve Life Sciences is developing a smoking cessation drug. Its weekly stock price is extremely volatile and depends entirely on news of its key clinical trial results and FDA approval prospects.
Weekly dynamics of market capitalization of the market segment - Narco farm
Achieve Life Sciences is developing a smoking cessation drug. This is a huge potential market, but launching a new drug is a long and risky process. The chart below shows how news about clinical trials creates a trend for the company's stock, independent of the rest of the pharmaceutical sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Achieve Life Sciences is a pharmaceutical company whose stock moves on news about clinical trials. It's a classic example of an asset that doesn't correlate with the market. The chart clearly demonstrates how much its performance is driven by scientific news.
Market capitalization of the company, segment and market as a whole
ACHV - Market capitalization of the company Achieve Life Sciences
Achieve Life Sciences' market capitalization chart is essentially a bet on a single product: cytisine, a smoking cessation drug. Its volatile chart reflects how investors assess its chances of FDA approval and its competition with existing nicotine addiction treatments. Any news about clinical trials triggers sharp price movements.
ACHV - Share of the company's market capitalization Achieve Life Sciences within the market segment - Narco farm
Achieve Life Sciences is a biopharmaceutical company developing a smoking cessation drug. Its market share currently reflects only the product's potential. Its market capitalization is a bet on the company's ability to offer smokers a new and effective way to quit.
Market capitalization of the market segment - Narco farm
Here's a chart showing the biotech sector's market capitalization. Achieve Life Sciences is a company focused on one goal: bringing cytisine to market as a smoking cessation aid. The potential of this market is enormous. Achieve's performance, compared to this, is a classic biotech "all or nothing" story, where the success of one drug can change everything.
Market capitalization of all companies included in a broad market index - GURU.Markets
Achieve Life Sciences is developing a cytisine-based smoking cessation drug, which has long been used in Eastern Europe. Its market capitalization is based on bringing this drug to the US market. The chart below shows the economic impact of smoking cessation.
Book value capitalization of the company, segment and market as a whole
ACHV - Book value capitalization of the company Achieve Life Sciences
Achieve Life's book value is derived from its intellectual property, cytisiniclin, a smoking cessation drug. The chart tells the story of a late-stage biotech company whose book value is derived from the capital required to secure FDA approval, which could create a multibillion-dollar intangible asset.
ACHV - Share of the company's book capitalization Achieve Life Sciences within the market segment - Narco farm
Achieve Life Sciences is developing a smoking cessation drug. The chart shows its share of actual R&D assets. These include its clinical programs and laboratories, which provide the necessary resources to bring this potentially revolutionary drug to market.
Market segment balance sheet capitalization - Narco farm
Achieve Life Sciences is a biotech company whose value lies in its development portfolio. Its business is capital-light. The chart below reflects the capital intensity of the pharmaceutical sector, which underscores its R&D-focused model.
Book value of all companies included in the broad market index - GURU.Markets
Achieve Life Sciences is developing a smoking cessation drug. The company's assets are its clinical program. A modest stake in BCap_All is a material resource aimed at solving one of the world's most serious public health problems.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Achieve Life Sciences
Achieve Life Sciences is a pharmaceutical company. Its entire market capitalization is a premium to its cash flow, which is a bet that its smoking cessation drug will be successful and capture a large market share.
Market to book capitalization ratio in a market segment - Narco farm
Achieve Life Sciences is developing a smoking cessation drug. Its valuation is based almost entirely on the potential of this single product. The chart shows the premium to book value that investors are paying for the hope of success in solving a major social problem.
Market to book capitalization ratio for the market as a whole
Achieve Life Sciences is developing a smoking cessation drug. This represents a huge potential market, but clinical trials also carry high risks. This chart demonstrates how market value in biotech can be detached from book value, reflecting investor hopes for a blockbuster.
Debts of the company, segment and market as a whole
ACHV - Company debts Achieve Life Sciences
Achieve Life Sciences, a company developing a smoking cessation drug, is raising capital to conduct late-stage clinical trials. The debt burden reflects the high costs associated with conducting the large-scale studies required to obtain FDA approval, a key step toward commercialization.
Market segment debts - Narco farm
Achieve Life Sciences is developing a smoking cessation drug. This is a huge market, but bringing a new drug to market requires large-scale and expensive clinical trials. This chart shows the company's financial strategy for this long journey: whether it relies on equity or other funding instruments to finance its research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Achieve Life Sciences
Achieve Life Sciences is developing a smoking cessation drug. The company's success depends entirely on the results of clinical trials and subsequent regulatory approval. This chart shows the company's leverage to finance this lengthy and expensive process, a key indicator of its financial risk.
Market segment debt to market segment book capitalization - Narco farm
Achieve Life Sciences is developing cytisinicline as a smoking and vaping cessation aid. The chart shows debt trends in the pharmaceutical sector. For a company in the clinical trials stage, this allows them to assess how they are funding their research to bring a potentially marketable product to market and how this impacts their financial profile.
Debt to book value of all companies in the market
Achieve Life Sciences is developing a smoking cessation drug. Currently in clinical trials, the company has no revenue and relies entirely on equity capital to finance its operations. This graph of the economy's overall debt burden clearly demonstrates that Achieve's financial model is a venture capital bet on the success of a single product, rather than on leveraging its operations.
P/E of the company, segment and market as a whole
P/E - Achieve Life Sciences
Achieve Life Sciences is developing a drug for smoking cessation and nicotine addiction. This chart shows investor expectations for the potential launch of this new, effective treatment. The company's valuation is based not on current profits, but on the size of the market it targets and the success of clinical trials.
P/E of the market segment - Narco farm
This chart shows the average valuation for biotech companies, providing context for Achieve Life Sciences. It reflects overall sentiment in the sector. Comparisons with this valuation help understand how the market views Achieve's smoking cessation potential and whether it believes it can compete with existing nicotine addiction treatments.
P/E of the market as a whole
Achieve Life Sciences is developing a smoking cessation drug. This represents a huge potential market, but the road to it is long and risky. This chart of overall biotech risk appetite shows whether investors are willing to fund a company whose success depends on a single product, even if its potential market is enormous.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Achieve Life Sciences
Achieve Life Sciences is a pharmaceutical company developing a smoking cessation drug. This graph reflects expectations for the potential commercial launch of a new therapy for nicotine addiction. The estimate is heavily dependent on the results of final-stage clinical trials and its ability to compete with existing treatments.
%20P%2FE%20Achieve%20Life%20Sciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Achieve-Life-Sciences&v=1772639888939 "Chart of the company's future (projected) P/E Achieve Life Sciences")
Future (projected) P/E of the market segment - Narco farm
Achieve Life Sciences is developing a drug for smoking cessation and nicotine addiction. This chart reflects investor expectations for the company's profitability relative to the sector. It allows one to assess the market's confidence in the drug's potential to become a new, effective therapy for millions of smokers worldwide.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Narco-farm&v=1772639889027 "Future (projected) P/E graph of the market segment - Narco farm")
Future (projected) P/E of the market as a whole
Achieve Life Sciences is developing a smoking cessation drug. For a late-stage biopharmaceutical company like Achieve, this market sentiment graph is important. Their success depends on clinical trial results and regulatory approval, but market optimism facilitates raising the capital needed for the product's commercial launch.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772639889083 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Achieve Life Sciences
Achieve Life Sciences is developing cytisinicline as a treatment for smoking cessation and nicotine addiction. This chart shows the company's financial position as it moves toward commercialization of this potentially popular drug.
Profit of companies in the market segment - Narco farm
Achieve Life Sciences is developing a drug for smoking cessation and nicotine addiction. This graph shows the profitability of the pharmaceutical sector. For ACHV, this reflects the enormous social need for effective and safe smoking cessation methods. Success in their clinical trials could unlock a multi-billion dollar market.
Overall market profit
Achieve Life Sciences is developing cytisinicline as a smoking cessation aid. This represents a huge potential market. The company's success depends entirely on the results of clinical trials and FDA approval. The overall economic trends shown in this chart have no bearing on this process.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Achieve Life Sciences
Achieve Life Sciences is developing cytisinicline as a smoking and vaping cessation aid. The revenue projections presented here are speculative and depend on the results of Phase III clinical trials and subsequent FDA approval. This is a bet on the huge market for nicotine addiction treatment.
%20profit%20of%20the%20company%20Achieve%20Life%20Sciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Achieve-Life-Sciences&v=1772639889190 "Graph of future (projected) profit of the company Achieve Life Sciences")
Future (predicted) profit of companies in the market segment - Narco farm
Achieve Life Sciences is developing a smoking cessation drug. The company's revenue forecast depends on the success of clinical trials and its ability to compete with existing treatments. This chart reflects analyst expectations for the vast but complex market for nicotine addiction treatments.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Narco-farm&v=1772639889200 "Graph of future (predicted) profits of companies in a market segment - Narco farm")
Future (predicted) profit of the market as a whole
Achieve Life Sciences is developing a smoking cessation drug. The company's success depends on clinical trial results and regulatory approval. The market profit forecasts presented here impact the overall investment climate, which determines the company's ability to fund its development prior to market entry.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772639889235 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Achieve Life Sciences
Achieve Life Sciences is developing cytisinicline as a smoking and vaping cessation aid. This chart shows a speculative valuation. Investors are betting the company will be able to offer a safer and more effective alternative to existing nicotine addiction treatments in a huge market.
P/S market segment - Narco farm
Achieve Life Sciences is developing a cytisine-based drug for smoking cessation and nicotine addiction. It is a potential alternative to existing treatments. This chart shows the average revenue estimate for the pharmaceutical sector, which helps understand how investors view Achieve's potential to address this global problem.
P/S of the market as a whole
Achieve Life Sciences is a pharmaceutical company developing cytisinicline as a treatment for smoking cessation and nicotine addiction. The company's success depends entirely on clinical trial results and regulatory approval. This chart provides a general market backdrop for assessing investor sentiment toward high-risk biotech companies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Achieve Life Sciences
Achieve Life Sciences is developing a treatment for smoking cessation and nicotine addiction. This chart shows how the market values the company based on its future revenue potential. It reflects the enormous need for new, effective, and safe treatments for addiction.
%20P%2FS%20Achieve%20Life%20Sciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Achieve-Life-Sciences&v=1772639889349 "The graph of the company's future (projected) P/S Achieve Life Sciences")
Future (projected) P/S of the market segment - Narco farm
Achieve Life Sciences is developing cytisinicline as a treatment for smoking cessation and nicotine addiction. This chart reflects investors' hopes that its product will become an effective and safe alternative to existing treatments in the vast smoking cessation market.
%20P%2FS%20market%20segment%20graph%20-%20Narco%20farm&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Narco-farm&v=1772639889380 "Future (projected) P/S market segment graph - Narco farm")
Future (projected) P/S of the market as a whole
Achieve Life Sciences is developing a smoking cessation drug. Their success depends entirely on the results of clinical trials and regulatory approval. This market optimism is vital for ACHV. Funding such public health-focused projects requires investors' confidence in the long-term commercial prospects.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772639889403 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Achieve Life Sciences
Achieve Life Sciences is a clinical-stage pharmaceutical company focused on developing a smoking cessation medication. Currently, the company has no commercial products. This timeline will determine whether its drug, cytisinicline, can become a viable alternative to existing nicotine addiction treatments.
Sales of companies in the market segment - Narco farm
Achieve Life Sciences is a pharmaceutical company focused on a single product: cytisinicline, a herbal smoking cessation medication. Their goal is to offer a more effective and safer solution for nicotine addiction. Being in late-stage development, the company has no revenue yet.
Overall market sales
Achieve Life Sciences is developing a treatment for smoking cessation and nicotine addiction. Given the enormous health risks of smoking, a successful product could have significant social and commercial impact. This total revenue chart includes the healthcare sector, where ACHV is working to address one of the most serious public health challenges.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Achieve Life Sciences
Achieve Life Sciences is developing cytisinicline as a smoking cessation aid. This drug has the potential to be an effective and safe alternative to existing methods. This schedule reflects expectations for the success of clinical trials and the commercial potential of this drug.
%20sales%20of%20the%20company%20Achieve%20Life%20Sciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Achieve-Life-Sciences&v=1772639889613 "Schedule of future (projected) sales of the company Achieve Life Sciences")
Future (projected) sales of companies in the market segment - Narco farm
Achieve Life Sciences is developing a smoking cessation and nicotine addiction treatment based on the plant alkaloid cytisine. This chart shows forecasts for the vast smoking cessation market. It reflects the potential for new, more effective, and safer medications that could help millions of people quit smoking.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Narco-farm&v=1772639889623 "Schedule of future (projected) sales of companies in the market segment - Narco farm")
Future (projected) sales of the market as a whole
Achieve Life Sciences, which is developing a smoking cessation drug, sees this chart as a reflection of global healthcare trends. Rising overall economic forecasts allow governments and healthcare systems to invest more in smoking cessation programs. This creates a potential market for the new, effective drug Achieve is developing.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772639889644 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Achieve Life Sciences
Achieve Life Sciences is a pharmaceutical company focused on developing a smoking cessation drug. Being in late-stage clinical trials, it incurs significant expenses. This chart doesn't show current profits, but rather the investment required to bring a potentially marketable product that could transform the company's financial picture.
Market segment marginality - Narco farm
Achieve Life Sciences is developing a drug for smoking cessation and nicotine addiction. This graph reflects the enormous commercial potential of this product. If successful, future operating revenue could be very high due to the global scale of the smoking problem and the need for new treatments.
Market marginality as a whole
Achieve Life Sciences is a late-stage pharmaceutical company developing a smoking cessation drug. Its valuation is entirely dependent on clinical trial results and future regulatory approval. This gross profitability chart doesn't reflect the huge potential market and the binary risks associated with drug development.
Employees in the company, segment and market as a whole
Number of employees in the company Achieve Life Sciences
Achieve Life Sciences is developing cytisinicline, a plant-based drug for smoking cessation and nicotine addiction. This graphic shows the small team conducting clinical trials of this potential non-nicotine treatment, targeting a huge global market.
Share of the company's employees Achieve Life Sciences within the market segment - Narco farm
Achieve Life Sciences is developing cytisinicline as a smoking and vaping cessation aid. If successful, this drug could help millions of people. Conducting large-scale clinical trials requires a growing team. This graph demonstrates the company's potential to become a significant player in the vast addiction treatment market.
Number of employees in the market segment - Narco farm
Achieve Life Sciences is developing a smoking cessation drug based on cytisine, a plant alkaloid. This graphic shows the team's efforts to bring to market a safer and more effective alternative to existing nicotine addiction treatments, solving one of the most serious public health problems.
Number of employees in the market as a whole
Achieve Life Sciences, Inc. is developing a smoking cessation drug. The overall economic situation, reflected in this chart, impacts their potential market. Stable employment and financial security can provide people with the incentive and resources to improve their health, including quitting unhealthy habits. Furthermore, employers are increasingly supporting such initiatives.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Achieve Life Sciences (ACHV)
Achieve Life Sciences is developing a smoking cessation drug. This chart represents their assessment of the potential solution to a huge social problem. The company's very high market capitalization per employee reflects the market's belief that their drug, if successful, will become a global blockbuster. This is a bet on a huge market and the effectiveness of a small scientific team.
%20of%20the%20company%20Achieve%20Life%20Sciences%20(ACHV)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Achieve-Life-Sciences-ACHV&v=1772639889885 "Chart of market capitalization per employee (in thousands of dollars) of the company Achieve Life Sciences (ACHV)")
Market capitalization per employee (in thousands of dollars) in the market segment - Narco farm
Achieve Life Sciences is a pharmaceutical company focused on developing a smoking cessation drug. Its market capitalization depends on the success of clinical trials and future commercial potential. This chart shows how investors value its leading asset, based on its small development team, compared to other pharmaceutical companies.
%20by%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Narco-farm&v=1772639889934 "Market capitalization per employee (in thousands of dollars) by market segment - Narco farm")
Market capitalization per employee (in thousands of dollars) for the overall market
Achieve Life Sciences is developing cytisinicline as a smoking cessation aid. This valuation reflects the company's huge potential market. The high valuation reflects investors' hope that the company will be able to offer an effective and safe alternative to existing nicotine addiction treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772639890008 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Achieve Life Sciences (ACHV)
Achieve Life Sciences is a clinical-stage biotech company whose sole asset is cytisine, a smoking cessation drug. This graph is negative. The company's small staff is focused on conducting crucial Phase III clinical trials to bring a lower-cost alternative to Chantix to the US market.
%20Chart%20Achieve%20Life%20Sciences%20(ACHV)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Achieve-Life-Sciences-ACHV&v=1772639890025 "Company Profit Per Employee (in thousands of dollars) Chart Achieve Life Sciences (ACHV)")
Profit per employee (in thousands of dollars) in the market segment - Narco farm
Achieve Life Sciences (ACHV) is a pharmaceutical company developing citisincline, a herbal treatment for smoking cessation and nicotine addiction. This chart represents an industry benchmark. It serves as a benchmark for the company during the R&D stage, demonstrating the potential profitability the industry is striving for if their drug is successful in the vast smoking cessation market.
%20in%20the%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Narco-farm&v=1772639890041 "Chart of profit per employee (in thousands of dollars) in the market segment - Narco farm")
Profit per employee (in thousands of dollars) for the market as a whole
Achieve Life Sciences (ACHV) is a biotech company focused on a single product (Cytisinicline), a smoking cessation drug. This is a late-stage R&D company. The chart shows the R&D investment (negative return) per employee required to conduct final clinical trials to compete with existing methods.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772639890051 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Achieve Life Sciences (ACHV)
Achieve Life Sciences is developing a smoking cessation drug. This graph reflects the clinical development stage. If the product is successful and approved, the dramatic increase in revenue per employee will demonstrate the enormous commercial potential of solving a significant public health problem affecting millions of people worldwide.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Achieve-Life-Sciences-ACHV&v=1772639890116 "Sales chart per company employee Achieve Life Sciences (ACHV)")
Sales per employee in the market segment - Narco farm
Achieve Life Sciences (ACHV) is a biotech focused on a single product: cytisine, a smoking cessation drug. They are in late-stage R&D and have no revenue. This chart reflects their R&D stage: they have a staff of clinicians but no sales, which is in stark contrast to the industry average.
Sales per employee for the market as a whole
Achieve Life Sciences is a biotech company focused on one goal: bringing a smoking cessation drug (Cytisinicline) to market. This is an R&D business. This graph will likely show zero revenue, as their team is in the final stages of clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Achieve Life Sciences (ACHV)
Achieve Life Sciences (ACHV) is a pharmaceutical company developing cytisinicline, a smoking cessation drug. This chart measures bearish bets. A high short position reflects investor doubts that the company will be able to successfully commercialize the drug or that it will compete with existing treatments for nicotine addiction.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Achieve-Life-Sciences-ACHV&v=1772639890362 "Short Shares Chart for the Company Achieve Life Sciences (ACHV)")
Shares shorted by market segment - Narco farm
Achieve Life Sciences (ACHV) is a pharmaceutical company focused on developing and commercializing cytisine, a smoking cessation drug, in the US. This chart illustrates the general skepticism in the biotech sector, reflecting investor doubts about the success of clinical trials and commercialization.
Shares shorted by the overall market
Achieve Life Sciences (ACHV) is developing a smoking cessation drug. It's a speculative biotech story. When this market fear indicator rises, investors' risk appetite plummets. They're unwilling to wait for FDA approval. They sell off unprofitable stocks like ACHV, whose fate hinges on a single binary event.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Achieve Life Sciences (ACHV)
Achieve Life Sciences is developing a smoking cessation drug. The stock is highly speculative. This chart can soar above 70 on positive trial data or FDA news, signaling euphoria. Oversold territory (<30) often reflects setbacks, delays, funding concerns, or general risk aversion in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Achieve-Life-Sciences-ACHV&v=1772639890452 "RSI 14 indicator chart for the company's stock Achieve Life Sciences (ACHV)")
RSI 14 Market Segment - Narco farm
Achieve (ACHV) is a nicotine "killer." It's a biotech company whose *single* bet is (Cytisinicline), a herbal smoking cessation drug. RSI_14_Seg for their biotech segment shows the "temperature." It helps us understand: is ACHV's volatility due to their R&D or is the *entire* sector "overheated?"
RSI 14 for the overall market
Achieve Life Sciences (ACHV) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ACHV (Achieve Life Sciences)
Achieve Life Sciences (ACHV) is a biotech company developing a drug (cytisiniclin) to aid smoking cessation. This chart shows the average target price. It reflects analysts' belief that this drug will gain FDA approval and capture a share of the multibillion-dollar smoking cessation market.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ACHV-Achieve-Life-Sciences&v=1772639890511 "A chart showing analyst consensus forecasts for the expected stock price. ACHV (Achieve Life Sciences)")
The difference between the consensus estimate and the actual stock price ACHV (Achieve Life Sciences)
Achieve Life Sciences is a one-stop shop. Its entire focus is on bringing cytisinicline, a herbal smoking cessation drug, to market. This chart shows how far the current stock price differs from the "fair" price predicted by analysts. The gap reflects their confidence in FDA approval and the company's enormous market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ACHV-Achieve-Life-Sciences&v=1772639890540 "A chart showing the difference between the consensus forecast and the actual stock price. ACHV (Achieve Life Sciences)")
Analyst consensus forecast for stock prices by market segment - Narco farm
Achieve Life Sciences is a biotech company developing cytisiniclin, a herbal drug designed to help people quit smoking (nicotine addiction). This chart shows general expectations for the pharmaceutical sector. It reflects whether experts believe in the potential of a new (or old) drug in the vast smoking cessation market.
Analysts' consensus forecast for the overall market share price
Achieve Life Sciences (ACHV) is a biotech company focused on a single product, cytisine. It's a herbal medicine they're trying to market in the US as a smoking cessation aid. This chart shows overall market sentiment. For ACHV, as an R&D company, it's important to consider how risk appetite (sentiment) influences their valuation. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Achieve Life Sciences
Achieve Life Sciences is a biotech company with one bet: cytisiniclin. It's a herbal smoking cessation drug (a competitor to Chantix), which they're trying to get FDA approval for. This chart is a clear indicator of their clinical trajectory. Its progress is all or nothing, depending entirely on their data and the regulator's final decision.
AKIMA Market Segment Index - Narco farm
Achieve Life Sciences is developing a drug (Cytisinicline) to help people quit smoking. It's a huge market, but with high barriers to entry. This chart shows the average pharmaceutical sector index. It allows investors to assess how Achieve's potential blockbuster compares to the sector average based on a combination of factors.
The AKIM Index for the overall market
Achieve Life Sciences is a pharmaceutical company developing cytisiniclin, a herbal smoking cessation drug. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, targeting the vast public health market, fits into the context of overall economic trends.
